Related Experiment Videos
Targeting the AXL signaling pathway in ovarian cancer
Ruby Yun-Ju Huang1, Jane Antony2, Tuan Zea Tan3
1Department of Obstetrics & Gynaecology, National University Hospital of Singapore, Singapore; Cancer Science Institute of Singapore, National University of Singapore, Singapore; Department of Anatomy, Yong Loo Lin School of Medicine, National University of Singapore, Singapore.
Abstract:
In a recent publication in Science Signaling, we showed that a Mes molecular subtype of epithelial ovarian cancer (EOC) harboring epithelial-mesenchymal transition (EMT) features has a unique signaling network downstream of the GAS6/AXL pathway. Our finding leads to a potential strategy for treating the Mes subtype of EOC by targeting AXL.
Insights
Researchers identified a unique signaling network in the Mes subtype of epithelial ovarian cancer (EOC) linked to epithelial-mesenchymal transition (EMT). Targeting the GAS6/AXL pathway offers a potential treatment strategy for this EOC subtype.
Area of Science:
- Oncology
- Molecular Biology
- Cell Signaling
Background:
- Epithelial ovarian cancer (EOC) comprises diverse molecular subtypes.
- The Mes subtype exhibits epithelial-mesenchymal transition (EMT) features.
- The GAS6/AXL pathway is implicated in various cancers.
Purpose of the Study:
- To elucidate the unique signaling network in the Mes subtype of EOC.
- To investigate the role of the GAS6/AXL pathway in Mes EOC.
- To identify potential therapeutic targets for Mes EOC.
Main Methods:
- Analysis of signaling networks in EOC subtypes.
- Investigating the GAS6/AXL pathway.
- Molecular and cellular assays.
Main Results:
- A distinct signaling network was identified downstream of GAS6/AXL in Mes EOC.
- The GAS6/AXL pathway plays a crucial role in the Mes subtype.
- EMT features are associated with this unique network.
Conclusions:
- The Mes subtype of EOC possesses a unique signaling profile.
- Targeting the AXL receptor tyrosine kinase presents a potential therapeutic strategy for Mes EOC.
- Further research into the GAS6/AXL pathway could yield novel treatments for ovarian cancer.